uniQure NV

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 10.57%69.230.0%$1059.52m
NVAXNovavax, Inc. 9.16%103.00251.8%$834.51m
AMGNAmgen, Inc. 1.21%252.061.3%$702.20m
REGNRegeneron Pharmaceuticals, Inc. 0.92%626.592.5%$669.14m
GILDGilead Sciences, Inc. 1.26%77.281.0%$638.74m
BIIBBiogen, Inc. 0.64%280.671.6%$605.43m
VRTXVertex Pharmaceuticals, Inc. 0.20%295.051.9%$476.49m
VXRTVaxart, Inc. 29.57%10.340.0%$371.75m
ILMNIllumina, Inc. 1.61%376.223.5%$306.04m
ALXNAlexion Pharmaceuticals, Inc. 0.63%109.502.0%$218.54m
BMRNBioMarin Pharmaceutical, Inc. 1.69%128.194.3%$210.30m
SGENSeattle Genetics, Inc. 0.56%175.326.1%$193.46m
SRNESorrento Therapeutics, Inc. -1.30%7.961.8%$190.46m
IMMUImmunomedics, Inc. 1.79%42.0611.0%$180.17m
BNTXBioNTech SE 13.66%79.970.0%$177.93m

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.